Navigation Links
Questcor to Commence Phase 2 Study of Acthar for ALS
Date:7/24/2013

ddition to this ALS trial, Questcor has on-going trials in idiopathic membranous nephropathy, systemic lupus erthymatosus, and diabetic nephropathy," continued Dr. Young. "These trials, combined with many mechanism of action studies and numerous Questcor-sponsored investigator initiated studies, are aimed at building the body of evidence surrounding the safety and efficacy of Acthar in both on-label and potential new indications."

For more information on studies related to Acthar, investors are encouraged to visit http://www.clinicaltrials.gov.

About ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed. The effect of this disease is not only a significant decrease in one's quality of life but also a decrease in life expectancy to an average of two to five years. At this time there is an unmet medical need for ALS treatments that significantly improve quality of life and/or extend survival.

ALS was first described in 1869 by French neurologist Jean-Martin Charcot, but it wasn't until 1939 that Lou Gehrig brought national and international attention to the disease when he abruptly retired from baseball after being diagnosed with ALS. Most commonly, the disease strikes people between the ages of 40 and 70, and as many as 30,000 Americans have the disease at any given time.

About Questcor        &#
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Questcor to Report Second Quarter Financial Results on July 30, 2013
2. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
3. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
4. Questcor Adds Angus C. Russell to Board of Directors
5. Questcor Reports First Quarter Financial Results
6. Questcor to Report First Quarter Results on April 30, 2013
7. Questcor Reports Fourth Quarter and Full Year 2012 Results
8. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... et SAN DIEGO , 29 ... (ci-après désignée Daiichi Sankyo) (TSE : 4568) et Ambit ... conclusion d,un accord de fusion définitif en vertu ... des actions ordinaires en circulation d,Ambit Biosciences à ... biais d,une offre publique d,achat qui sera suivie ...
(Date:9/29/2014)... , Sept. 29, 2014  Bob Pack, who lost ... called on the California Medical Association to immediately cease ... that the San Jose Mercury News called "shamelessly deceptive" ... it wants voters to believe about the measure is ... the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... York, New York (PRWEB) September 30, 2014 ... honor Kenro Izu – founder of the nonprofit, Friends ... on November 6, 2014, for building a hospital in ... pediatric care. , Izu first encountered Cambodia’s appalling ... from a variety of disabilities and illnesses during a ...
(Date:9/30/2014)... OH (PRWEB) September 30, 2014 ... blades sporting the iconic pink ribbon in support of ... a popular month for businesses and non-profits to “go ... worthwhile cause. , AutoTex PINK is a woman-owned company ... wipers. They are committed to partnering with their ...
(Date:9/30/2014)... September 30, 2014 Teeth replacement and ... Art Institute in Oxnard and Thousand Oaks, Calif., is ... tomorrow to provide training on full mouth rehabilitation. , ... placing implants, providing cosmetic dentistry, correcting bite issues, and ... , Dr. Jivraj, who has traveled to India to ...
(Date:9/30/2014)... 30, 2014 Loffler Companies, an ... technology and services was recognized by BEI as ... (FCE) in 2013. This prestigious rating means that ... time and for an extended period following, optimizing ... 20 years BEI Services has been the trusted ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 In ... commemorate breast cancer survivors and their courageous battles, Incredible ... to start afresh with PicoSure® by Cynosure. , ... blue or black tattoo is applied on their skin ... explains Dr. Sam Ebrahimi. “For many survivors, they decide ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2
... A team of scientists, based in UK, have grown ... successful attempt to control the development of embryonic stem ... production of replacement tissues for treating neurodegenerative conditions like ... in heavy competition over the past few years to ...
... have hailed the results of early studies into a ... out by US doctors on an anti-depression 'pacemaker' found ... of patients.// ,The pacemaker, which is implanted ... left vagus nerve in the brain. The device was ...
... if women drink too much coffee during pregnancy can increase ... have found that caffeine may be linked to the development ... been briefly starved of oxygen. ,A research team from ... from the hippocampus, a part of the brain that is ...
... Year with a resolution to get fit are urged ... could cause damage that leads to arthritis in later ... joints in their 20s and 30s are at greater ... they get older. The Arthritis Research Campaign says that ...
... other salad goods may help reduce the risk of osteoporosis ... women, usually after the menopause. Reported researchers at the ... ,They said that 1g of onion a day ... resorption, where calcium seeps from the bones making them brittle. ...
... eradicated by 1979 and vaccination against the disease gradually ... virus remain in laboratories in the US, Russia and ... concerns that these stockpiles could be used to introduce ... at present ill-prepared to deal with a potential outbreak. ...
Cached Medicine News:Health News:Stem cell research 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: